The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Will be MHRA sign off on rtc antibody. Nobody can announce anything until we have that
for disrupting the BB...if enough people do it they'll ban him. He's clearly completely clueless and is literally only on here to wind people up...either that or filter the tool...he'll be going to school in a minute so will stop posting until half 3
ADV11..completely wrong chap I'm afraid. If their portfolio becomes too weighted due to price increase they have to sell down...they're not some PI that personally decides when to hold and when to buy..do you not have a clue about how 2's work and their balanced portfolio risk management?
They'll be gone soon so another anchor shifted in readiness for the re-rate...
All the MHRA are signing off is the ease of use of the product..the accuracy and lab test is already approved. They had 2000 people use it in their cars over the weekend..what was the combined feedback from them? Is it capable to be sent out to members of the public to be used properly..i.e Can they read simple instructions and prick one of their fingers? We know it's **** easy to use..it just needs rubber stamping...won't take long.
Motley always err on the side of caution for small caps..they usually say sell....All these revenues are conservative
getting involved in Omega now and they're usually ultra pessimistic about small caps..just the 100% upside for them..
Omega Diagnostics share price: need-to-know
The coronavirus pandemic has been a boon for Omega. The company is planning to produce as many as five different types of Covid-19 tests.
The self-test usability study for one of these, the AbC-19 Rapid Test, was completed last weekend. This put the product one step closer to coming to market.
As well as the Rapid antibody Test, at the beginning of September, Omega’s Mologic Covid-19 lateral flow antibody test was awarded its CE Mark. This quality marking means the business can now start marketing and selling the product.
These Covid tests are not the only strings to Omega’s bow. The group has three operating segments. As well as the coronavirus testing segment, there’s a division specialising in allergies and food intolerances. The third segment provides HIV testing equipment. This provides some diversification for the business.
Unfortunately, the company remains in its early stages. It’s not yet self-sufficient, which could be a red flag for investors looking at the Omega Diagnostics share price.
Earlier this year, the group raised £11m from investors to scale up production. While demand for the company’s products will provide much-needed cash flow, I wouldn’t rule out another cash raise in future as the business finds its feet.
Still, despite this drawback, it’s clear the business has tremendous potential.
Financial broker finnCap reckons Omega could ultimately be looking at £8m-£12m of revenue from its food intolerance testing business and £37m in revenues from Covid test sales. The group’s HIV test, VISITECT CD4, could be worth between £45m to £75m.
100% upside?
Based on these projections, the Omega Diagnostics share price looks cheap after its recent performance.
In the best case, the projections above suggest the business has the potential to generate £124m in annual revenues. Quest Diagnostics Inc is one of the largest testing companies in the world. And that stock is currently trading at a multiple of two times sales.
Based on this, it’s not unreasonable to suggest Omega could be worth as much as £248m in the best-case scenario.
However, I should stress this is the best-case scenario. The company is still finding its way, and a lot could wrong between now and annual sales of £124m.
That said, it’s clear there’s a tremendous amount of potential here. With upside potential as much as 100%, investors could be well rewarded if the company gets everything right.
Therefore, the best solution may be to own the stock as part of a diversified portfolio. Doing so would minimise downside risk while providing exposure to profits if the Omega Diagnostics share price continues to surge in value.
on the LOI without even thinking what the added value is for ORCP. Hold from here for18 months and what do you think the sp will be with other projects thrown into the mixer. You don't get this calibre of people involved and Sheikhs chucking millions in without big returns...bet many people won't be around in that time frame but that's where the serious money is to be made...
Like a breathalyser...it's coming.
You don't set up a Government lead consortium to develop and manufacture tests, to the highest standard in the world, assessed and finally approved by said Government, to then not give the orders to the consortium. All those that think getting the order is a big deal must be stupid. It's just jumping through the hoops to get sign off that's the time consuming bit..and organisations are involved that are outside of the consortium and the Government. It stands to the reason the Government will want to announce the deal and sing it from the rooftops as it's the best in the world...why wouldn't you? And any spare capacity will be taken up by private buyers...if you can't see what's coming, you must be blind ,stupid or both
it's hilarious...it's not like Government orders aren't coming you complete dimwits...just not released officially..this bb is full of loons